FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma By Ogkologos - October 27, 2025 59 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Single Mom Has To Beg For Rides To Doctor For Son... March 14, 2019 Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously... January 10, 2023 A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival... January 25, 2022 Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer? October 3, 2023 Load more HOT NEWS Paralyzed Bride Walks Down Aisle At Her Wedding & Surprises Groom Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,... Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group... Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board,...
